12.01.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes
DGAP-News: MorphoSys AG / Key word(s): Study
MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients
with Type 2 Diabetes
12.01.2017 / 09:09
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, January 12, 2017
MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients
with Type 2 Diabetes
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today that its partner Novartis will conduct a phase 2 clinical
trial of the HuCAL antibody bimagrumab in obese patients with type 2
diabetes.
According to information published on clinicaltrials.gov, the randomized,
subject- and investigator-blinded study will enroll 60 obese adult patients
with type 2 diabetes to assess the safety, pharmacokinetics and efficacy of
intravenous bimagrumab compared to placebo. The study is not yet open for
enrollment.
The study's primary outcome measures comprise the change in fat body mass
at weeks 24 and 48. Secondary outcome measures include mean change from
baseline in HbA1c, insulin resistance as measured by the homeostatic model
assessment (HOMA-IR), fasting insulin and glucose.
Further detailed information about the trial can be found at
clinicaltrials.gov.
"We are very excited that our partner Novartis is taking bimagrumab into a
phase 2 study in type 2 diabetes, an indication with growing demand for
novel treatments. This new study will join phase 2 clinical trials of
bimagrumab currently ongoing in patients with sarcopenia and after hip
fracture surgery", commented Dr. Marlies Sproll, Chief Scientific Officer
of MorphoSys AG.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
12.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
535747 12.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR